Article
MicroRNAs have the potential to be predictive biomarkers that can predict survival as well as response to chemotherapy, as this study discovered.
Tumor samples from recurrent lung adenocarcinoma patients treated with platinum-based doublet chemotherapy were analyzed for microRNA expression. The analysis identified a signature: miR1290, miR196b, and miR135a*. These 3 microRNAs could predict chemotherapy response, not progression-free survival or overall survival, in patients with recurrent lung cancer.
Link to the abstract in Clinical Cancer Research: http://bit.ly/1m5Ed8v
How to Choose Between Fixed-Duration vs Continuous BTKi Therapy for CLL